Uruguay is in a privileged situation, where exports to the main world markets are already taking place: Switzerland, Germany, Portugal, Israel and Australia.
With regard to Brazil, ANVISA regulated the registration of medicines in November 2019, and in January 2020 it simplified the process of importing medicines, but cultivation remains prohibited.
This demands the import of raw materials, and anyone with experience in cultivation in Uruguay will have an enormous advantage, considering the Mercosur agreements, which exempt import taxes and accept Uruguayan certifications.
There are 210 million inhabitants!
Anvisa estimates the Brazilian market at 13 million patients.